Skip to content
All resources

GLP-1 and metabolic

Amycretin: What the Trials of Novo Nordisk's GLP-1 and Amylin Agonist Show

AM

By

· 8 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 7 sections
  1. What is amycretin?
  2. What did the animal studies show?
  3. What did the first human trials find?
  4. What did the phase 2 diabetes trials find?
  5. What is in the AMAZE phase 3 programme?
  6. Is amycretin approved?
  7. Frequently asked questions

Amycretin is an investigational single molecule from Novo Nordisk that activates GLP-1, amylin and calcitonin receptors. It now carries the name zenagamtide. In a phase 1b/2a study in 125 adults with overweight or obesity, weight change ranged from −9.7% to −24.3% across study parts lasting 20 to 36 weeks, against −1.1% to +2.3% on placebo. Two phase 2 trials in type 2 diabetes met their HbA1c endpoints. The AMAZE phase 3 programme is recruiting. Amycretin is approved nowhere.

One peptide molecule bridging receptors on two neighbouring cells
Illustration: one molecule designed to act at two receptor families.

What is amycretin?

Amycretin is a unimolecular agonist, meaning one peptide with activity at more than one receptor family. The 2026 phase 2 papers describe zenagamtide, "formerly amycretin", as an agonist of GLP-1, amylin and calcitonin receptors. On ClinicalTrials.gov the same compound also appears under its Novo Nordisk code, NNC0487-0111. This article uses "amycretin" because that is still the name most people search, and because the earlier papers use it.

Its design differs from CagriSema, Novo Nordisk's other GLP-1 and amylin product. CagriSema is two separate peptides, semaglutide and cagrilintide, given together. Amycretin puts both activities into a single molecule. Whether that matters clinically, beyond convenience and a single pharmacokinetic profile, is not something the published trials have tested; there is no head-to-head comparison between the two.

Amylin receptors are not a single protein. They form when the calcitonin receptor pairs with one of three accessory proteins, which is why amylin-class compounds usually act at the calcitonin receptor too. That biology is set out in amylin receptors explained. The GLP-1 side is covered in the receptor guide.

What did the animal studies show?

Kuhre and colleagues at Novo Nordisk characterised amycretin in cells, mice and rats. It activated human, mouse and rat GLP-1, amylin and calcitonin receptors in cell-based assays. In diet-induced obese rats, 21 days of treatment cut total energy intake by 47% and lowered body weight by 18% relative to vehicle, while energy expenditure was maintained. In other words, the weight change in rats came from eating less, not from burning more. That is a different mechanism from the one proposed for glucagon receptor agonists. The compound reached brain areas involved in food intake in mice, and insulin sensitivity and liver steatosis scores improved in the rodent models. These are animal findings.

What did the first human trials find?

First-in-human phase 1. Gasiorek and colleagues ran a three-part trial in 144 adults with overweight or obesity at a single unit in San Antonio, testing single and multiple ascending doses of one formulation over periods up to 12 weeks. Its primary endpoint was the number of treatment-emergent adverse events. Across all parts, 62% of participants reported at least one, all mild or moderate, increasing with dose. Gastrointestinal events made up about half of all events. Plasma concentrations rose in proportion to dose. The weight findings were exploratory and are not reported in the abstract.

Phase 1b/2a. Dahl and colleagues tested the other formulation in 125 adults with overweight or obesity, aged 18 to 55, again at a single site in San Antonio. The study had five parts. Four of them were multiple-dose parts that escalated participants to different maintenance levels over 20 to 36 weeks. The primary endpoint was adverse events; weight change was a secondary endpoint.

Study partDurationWeight change, amycretinWeight change, placebo
Part B (highest escalation)36 weeks−24.3%−1.1%
Part C36 weeks−22.0%+1.9%
Part D28 weeks−16.2%+2.3%
Part E (lowest maintenance level)20 weeks−9.7%+2.0%

Those figures are striking, and the abstract itself flags the reason for caution: a large number of participants withdrew, a high proportion for reasons unrelated to adverse events. The parts were small, the placebo groups were pooled from 24 participants in total, and the setting was one research centre. The most common adverse events were gastrointestinal, mostly mild to moderate, and largely resolved by the end of the study.

What did the phase 2 diabetes trials find?

In 2026 Mora and colleagues published two 36-week, placebo-controlled, dose-finding phase 2 trials in adults with type 2 diabetes on metformin, with or without an SGLT2 inhibitor. They ran under one registration (NCT06542874) at 83 sites in 11 countries, each testing one of the two formulations. The primary endpoint in both was change in HbA1c at week 36.

First formulation. 262 participants were randomised across six dose levels or placebo. From a mean baseline HbA1c of 7.8%, HbA1c fell by between 0.9 and 1.7 percentage points across the doses studied. The placebo-adjusted differences ran from −0.77 to −1.56 points. Most adverse events were gastrointestinal and mild to moderate. Serious adverse events occurred in 21 of 261 treated participants (8%), spread across the active and placebo groups, and there were no deaths.

Second formulation. 186 participants were randomised across three dose levels or placebo. HbA1c fell by 0.9 to 1.4 points, with placebo-adjusted differences of −0.5 to −1.09. Gastrointestinal adverse events affected 26% to 47% of those on zenagamtide, against 23% on placebo. Serious adverse events occurred in seven participants on zenagamtide (4%) and none on placebo.

Both trials report HbA1c, the measure a diabetes programme is built on. Weight results are not given in either abstract, so they are not quoted here.

What is in the AMAZE phase 3 programme?

ClinicalTrials.gov lists a large phase 3 programme, all sponsored by Novo Nordisk and none yet reported. Some records use the name zenagamtide and others the code NNC0487-0111:

TrialPopulationActive comparator in registry titleRegistry
AMAZE 1Excess body weightNone namedNCT07339423
AMAZE 2Excess weight with type 2 diabetesNone namedNCT07533175
AMAZE 3 and 4Obstructive sleep apnoea, with and without airway pressure therapyNone namedNCT07571005, NCT07571109
AMAZE 5 and 6Knee osteoarthritisNone namedNCT07481630, NCT07509307
AMAZE 7Excess body weightSemaglutideNCT07668414
AMAZE 8Excess weight with type 2 diabetesSemaglutideNCT07400107
AMAZE 12Weight maintenanceNone namedNCT07503210
AMBITION 7Type 2 diabetes with raised cardiovascular riskInsulin glargineNCT07797335
HF-POLARISHeart failure with obesityPlaceboNCT07567001
AMBIENCEAtherosclerotic cardiovascular disease with overweight or obesityPlaceboNCT07861100

AMBIENCE, planned for 8,500 participants, is the cardiovascular outcomes trial, and it is listed as not yet recruiting, with primary completion projected for 2030. Until it and HF-POLARIS report, there is no outcome evidence for amycretin, only weight and glucose data from small early trials. Registry dates and designs can change; the guide to reading a ClinicalTrials.gov record explains what each field means.

Is amycretin approved?

No. No regulator has authorised amycretin or zenagamtide for any use, and its phase 3 programme was still recruiting in October 2026. Health Canada's Drug Product Database is where any Canadian authorisation would eventually appear.

Its position against the rest of the field, including the approved incretins and late-stage candidates such as survodutide, mazdutide and MariTide, is tabulated in the 2026 incretin pipeline overview. The selective amylin agonist being developed by a competitor is covered in eloralintide's phase 2 data.

NovaEvum does not carry amycretin. Nothing here is medical, dosing, or therapeutic guidance.

Frequently asked questions

Is amycretin the same as zenagamtide? Yes. Papers published in 2026 describe zenagamtide as "formerly amycretin", and ClinicalTrials.gov records use both names as well as the code NNC0487-0111. A new name for an investigational compound is routine in drug development and says nothing about its approval status.

How much weight did people lose on amycretin? In the phase 1b/2a study, weight change ranged from −9.7% at 20 weeks in the lowest-escalation part to −24.3% at 36 weeks in the highest, against −1.1% to +2.3% on placebo. The groups were small, at one site, and many participants withdrew. Phase 3 results do not exist yet.

How is amycretin different from CagriSema? CagriSema is two separate peptides, semaglutide and cagrilintide, given together. Amycretin is one molecule that activates GLP-1, amylin and calcitonin receptors. Both come from Novo Nordisk. No trial has compared them directly, so which approach performs better is unknown.

What are amycretin's side effects? In the published trials, mostly gastrointestinal events, generally mild to moderate and more frequent at higher doses. In one phase 2 diabetes trial, gastrointestinal events affected 26% to 47% of zenagamtide recipients against 23% on placebo. Serious adverse events occurred in 4% to 8% of participants across the two phase 2 trials.

Selected Research References

  1. Kuhre RE, Ballarín-González B, Brand CL, et al. The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats. EBioMedicine. 2025;118:105862. pubmed.ncbi.nlm.nih.gov/40706446
  2. Gasiorek A, Heydorn A, Gabery S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. The Lancet. 2025;406:135-148. pubmed.ncbi.nlm.nih.gov/40550229
  3. Dahl K, Toubro S, Dey S, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. The Lancet. 2025;406:149-162. pubmed.ncbi.nlm.nih.gov/40550231
  4. Mora P, Aroda VR, Asong M, et al. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. The Lancet. 2026;408:621-635. pubmed.ncbi.nlm.nih.gov/42532080
  5. Mora P, Aroda VR, Asong M, et al. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. The Lancet. 2026;408:607-620. pubmed.ncbi.nlm.nih.gov/42532079

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.